| Revision as of 14:24, 12 January 2012 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{drugbox}} (changes to verified fields - added verified revid - updated 'UNII_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref') per Chem/Drugbox validation (report [[Misplaced Pages talk:WikiProject_Pharmacol...← Previous edit |
Latest revision as of 20:57, 1 December 2023 edit undoBuidhe (talk | contribs)Autopatrolled, Extended confirmed users, Page movers, File movers, Mass message senders, New page reviewers, Pending changes reviewers, Template editors136,075 editsm Moving from Category:Experimental drugs to Category:Experimental monoclonal antibodies using Cat-a-lot |
| (15 intermediate revisions by 13 users not shown) |
| Line 1: |
Line 1: |
|
⚫ |
{{Short description|Monoclonal antibody}} |
|
{{Drugbox |
|
{{Drugbox |
|
| Verifiedfields = changed |
|
| Verifiedfields = changed |
|
|
| Watchedfields = changed |
|
| verifiedrevid = 470478505 |
|
| verifiedrevid = 470478505 |
|
| image = |
|
| image = |
|
|
<!-- Monoclonal antibody data --> |
|
|
|
| ⚫ |
<!--Monoclonal antibody data--> |
|
|
| type = mab |
|
| type = mab |
|
| mab_type = mab |
|
| mab_type = mab |
|
| source = zu/o |
|
| source = zu/o |
|
| target = ] |
|
| target = ] |
|
⚫ |
<!-- Clinical data --> |
|
|
|
|
⚫ |
| tradename = Aurexis |
| ⚫ |
<!--Clinical data--> |
|
| ⚫ |
| tradename = |
|
|
| pregnancy_AU = |
|
| pregnancy_AU = |
|
| pregnancy_US = |
|
| pregnancy_US = |
| Line 21: |
Line 21: |
|
| legal_status = |
|
| legal_status = |
|
| routes_of_administration = |
|
| routes_of_administration = |
|
⚫ |
<!-- Pharmacokinetic data --> |
|
|
|
| ⚫ |
<!--Pharmacokinetic data--> |
|
|
| bioavailability = |
|
| bioavailability = |
|
| protein_bound = |
|
| protein_bound = |
| Line 28: |
Line 27: |
|
| elimination_half-life = |
|
| elimination_half-life = |
|
| excretion = |
|
| excretion = |
|
⚫ |
<!-- Identifiers --> |
|
|
|
|
⚫ |
| CAS_number_Ref = {{cascite|changed|CAS}} |
| ⚫ |
<!--Identifiers--> |
|
| ⚫ |
| CAS_number_Ref = {{cascite|changed|??}} |
|
|
| CAS_number = 521079-87-8 |
|
| CAS_number = 521079-87-8 |
|
|
| UNII_Ref = {{fdacite|changed|FDA}} |
|
|
| UNII = SBO7Q9G95R |
|
| ATC_prefix = none |
|
| ATC_prefix = none |
|
| ATC_suffix = |
|
| ATC_suffix = |
| Line 39: |
Line 39: |
|
| KEGG_Ref = {{keggcite|correct|kegg}} |
|
| KEGG_Ref = {{keggcite|correct|kegg}} |
|
| KEGG = D06054 |
|
| KEGG = D06054 |
|
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} |
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
|
| ChemSpiderID = NA |
|
| ChemSpiderID = none |
|
⚫ |
<!-- Chemical data --> |
|
|
|
|
⚫ |
| C=6548 | H=10122 | N=1730 | O=2034 | S=44 |
| ⚫ |
<!--Chemical data--> |
|
| ⚫ |
| C=6548 | H=10122 | N=1730 | O=2034 | S=44 |
|
|
| molecular_weight = 147.590 ] |
|
|
}} |
|
}} |
|
|
|
|
|
'''Tefibazumab''' (marketed under the brand name '''Aurexis''') is a ] for the treatment of severe infections with '']''. Possible indications include the treatment of ''S. aureus'' in patient with ]<ref>{{ClinicalTrialsGov|NCT00198289}}</ref> and of ].<ref>{{pmid|18221183}}</ref> |
|
'''Tefibazumab''' (named '''Aurexis''' but not approved) is a ] for the treatment of severe infections with '']''. Possible indications include the treatment of ''S. aureus'' in a phase 2a patients with ]<ref>{{ClinicalTrialsGov|NCT00198289|Aurexis in Cystic Fibrosis Subjects Chronically Colonized With Staphylococcus Aureus in Their Lungs}}</ref> and of ].<ref>{{cite journal | vauthors = Pan A, Lorenzotti S, Zoncada A | title = Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection | journal = Recent Patents on Anti-Infective Drug Discovery | volume = 3 | issue = 1 | pages = 10–33 | date = January 2008 | pmid = 18221183 | doi = 10.2174/157489108783413173 }}</ref> |
|
|
|
|
|
It was developed by Inhibitex.<ref name="pmid17078388">{{cite journal |author=John JF |title=Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection |journal=Curr. Opin. Mol. Ther. |volume=8 |issue=5 |pages=455–60 |year=2006 |pmid=17078388 |doi=}}</ref> |
|
It was developed by Inhibitex.<ref name="pmid17078388">{{cite journal | vauthors = John JF | title = Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection | journal = Current Opinion in Molecular Therapeutics | volume = 8 | issue = 5 | pages = 455–60 | date = October 2006 | pmid = 17078388 }}</ref> |
|
|
|
|
|
==See also== |
|
== See also == |
|
* ] (microbial surface components recognizing adhesive matrix molecules) |
|
* ] (microbial surface components recognizing adhesive matrix molecules) |
|
|
|
|
|
==References== |
|
== References == |
|
{{reflist}} |
|
{{reflist}} |
|
|
|
|
| Line 60: |
Line 58: |
|
|
|
|
|
] |
|
] |
|
|
] |
|
|
|
|
|
|
|
{{antiinfective-drug-stub}} |
|
{{antiinfective-drug-stub}} |
|
{{monoclonal-antibody-stub}} |
|
{{monoclonal-antibody-stub}} |
